19.3%
of Black children in the US have atopic dermatitis vs. 16.1% of white and 7.8% of Asian children (NHANES analyses, JACI 2021)
Overview
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease driven by skin-barrier dysfunction (often filaggrin-related), type 2 immune activation, and itch-scratch amplification. It usually starts in infancy or early childhood, flares and remits for years, and in many patients persists into adulthood. Itch is the defining symptom: patients with AD scratch, the scratching damages the barrier further, and the inflammation cycles.
AD is the entry point of the atopic march, the pattern in which infant eczema is followed by food allergy, allergic rhinitis, and asthma in a meaningful share of children. Roughly half of children with eczema go on to develop asthma and about a third develop food allergy.
How Atopic Dermatitis on Black Skin affects Black patients
The textbook picture of eczema is pink, weepy patches on flexures. That picture is built from white skin. On Black skin the inflammation reads differently and the disease often looks different at the level of the lesion itself, which is one reason recognition and treatment lag.
Color of inflammation. Erythema on darkly pigmented skin commonly appears violaceous, gray-brown, or simply as hyperpigmentation rather than red. Wilson, Alexis, and Murase (International Journal of Women's Dermatology, 2022) warn clinicians not to rely on erythema scoring alone in darker skin because severity gets underestimated.
Morphology. A papular and follicular pattern is more common in patients of African descent. Weingarten and Silverberg (JAAD, 2022) reviewed the literature on follicular eczema and found these 1 to 2 mm perifollicular papules over the trunk and extensors are characteristic of darker skin types and routinely missed when clinicians are looking for confluent flexural plaques.
Pigmentary aftermath. Atopic dermatitis is one of the leading causes of post-inflammatory hyperpigmentation in skin of color (Davis et al., reviewed in PMC9709857, 2022). These pigment changes can persist for months after the inflammation is controlled and are often what patients are most distressed about.
Severity and persistence. Black children are roughly 1.7 to 2.1 times more likely than white children to be diagnosed with AD, more than twice as likely to have severe disease, and more than three times as likely to have persistent AD into later childhood (Croce, Wang, and Lipoff, JACI, 2021, PMC8578465).
Why it gets missed. Image audits of dermatology textbooks repeatedly find that 4 to 18 percent of clinical photographs depict darker skin (Adelekun, Onyekaba, and Lipoff; Louie and Wilkes; reviewed by Lester, PubMed 31157429). Medical students and residents are trained on a near-monochrome image set, then apply that pattern to every patient.
Symptoms
- Itch first, often before any visible lesion. Severe itch that disrupts sleep is the most reliable symptom across skin tones.
- Dry, scaly skin with poorly defined borders, often on the cheeks and scalp in infants, the flexures (inner elbows, behind the knees) in children, and the hands, eyelids, and neck in adults.
- Papular eczema: small 1 to 2 mm bumps clustered on the trunk and extensors, often without the classic plaques.
- Follicular accentuation: bumpy texture that follows hair follicles, especially on the chest, back, and abdomen.
- Lichenification: thickened, leathery skin with exaggerated skin lines from chronic rubbing.
- Post-inflammatory hyperpigmentation or hypopigmentation that outlasts the active flare.
- Periorbital darkening and infraorbital folds (Dennie-Morgan lines).
- Sleep disruption, daytime fatigue, and concentration problems driven by nighttime itch.
When to see a doctor
See a clinician if itch is interfering with sleep, school, or work, if over-the-counter moisturizers and 1 percent hydrocortisone are not controlling flares, or if rash is spreading. Get same-day care for signs of infection: honey-colored crust, pus, fever, rapidly worsening pain, or punched-out erosions (eczema herpeticum is a dermatologic emergency, particularly in children, and presents as monomorphic vesicles or punched-out ulcers on top of eczema). If you have been told you have "sensitive skin" or "ashy skin" for years and nothing has helped, ask specifically to be evaluated for atopic dermatitis.
Screening
There is no population screening test for atopic dermatitis. Diagnosis is clinical. The strongest risk signal is a personal or family history of atopy: a parent or sibling with eczema, asthma, allergic rhinitis (hay fever), or food allergy. If a child has eczema, current allergy and dermatology guidance is that the threshold to evaluate for the rest of the atopic march, especially food allergy in infants with moderate-to-severe AD, should be low.
Treatment overview
The American Academy of Dermatology's 2023 guidelines for AD in adults (Sidbury et al., JAAD, 2023, PubMed 36641009) make strong recommendations for daily moisturizers, topical corticosteroids as first-line anti-inflammatory therapy, topical calcineurin inhibitors (tacrolimus, pimecrolimus), the PDE-4 inhibitor crisaborole, and the topical JAK inhibitor ruxolitinib cream for mild-to-moderate disease.
For moderate-to-severe disease that fails topicals, systemic options now include the biologics dupilumab and tralokinumab and the oral JAK inhibitors upadacitinib and abrocitinib. Dupilumab's phase 3 trials showed comparable efficacy across racial subgroups including Black/African American patients (Alexis et al., 2019). Despite that, real-world prescribing is unequal: a Florida pediatric cohort found Black children had odds ratio 0.43 of receiving dupilumab compared to non-Hispanic white peers (Jonsdottir et al., JACI Global, 2024, PMC11492344), and a national matched cohort study found Black adults with AD had significantly lower odds of being prescribed dupilumab within 12 months of treatment initiation (Al-Obaydi et al., JACI in Practice, 2023, PubMed 37225123).
For patients prone to recurrent skin infections (particularly Staphylococcus aureus colonization), the AAD conditionally recommends dilute bleach baths plus intranasal mupirocin. Wet-wrap therapy is conditionally recommended for flares. Antihistamines are not recommended as a primary treatment for itch in AD.
Questions to ask your doctor
Bring this list to your next appointment.
- What stage and severity is my (or my child's) AD by EASI or IGA, and how did you score it given my skin tone?
- If topical steroids and moisturizers are not working after a reasonable trial, am I a candidate for dupilumab, tralokinumab, or an oral JAK inhibitor? If not, why not?
- Can you refer me to a dermatologist with documented experience in skin of color?
- What's the plan for the dark or light patches left after a flare clears? Is treating the inflammation enough, or do I need a separate plan for post-inflammatory hyperpigmentation?
- For a child with moderate-to-severe eczema: should we screen for food allergy, and should we have a pediatric allergist evaluate for asthma and allergic rhinitis as they get older?
- If we are using topical steroids long-term, what's the taper plan and how do we monitor for skin atrophy on flexures and face?
- Am I being offered the same treatment options that you would offer a white patient with this severity of disease?
Find a Dermatology
Search our directory of verified Black health providers who specialize in dermatology.
Browse Dermatology providersMedical disclaimer
This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. If you are experiencing a medical emergency, call 911 or your local emergency number immediately.